Compare SHIM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | LUNG |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 82.5M |
| IPO Year | 2023 | 2020 |
| Metric | SHIM | LUNG |
|---|---|---|
| Price | $3.70 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 50.8K | ★ 479.5K |
| Earning Date | 11-13-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,984,000.00 | $91,664,000.00 |
| Revenue This Year | $6.91 | $9.21 |
| Revenue Next Year | $13.03 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $1.30 | $1.31 |
| 52 Week High | $3.83 | $9.37 |
| Indicator | SHIM | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 35.31 |
| Support Level | $3.55 | $1.92 |
| Resistance Level | $3.83 | $2.03 |
| Average True Range (ATR) | 0.24 | 0.13 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 81.80 | 0.97 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.